Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanderbilt-Ingram Cancer Center
With
Wren Laboratories LLC
* Evaluate the diagnostic efficacy of a circulating melanoma gene signature in pathologically verified Stage III melanoma at diagnosis (biopsy-proven lymph node positive) and compare this to LDH as a biomarker.
* Evaluate the diagnostic efficacy of a circulating melanoma gene signature in pathologically verified Stage IV melanoma (including pre-surgery patients as well as those on either targeted or immunotherapy) and compare this to LDH as a biomarker.
* Define the assay metrics for sensitivity and specificity in diagnosis in Stage III and IV tumors.
* Monitor molecular signature levels in blood to assess efficacy of this tool as compared to imaging or other biomarkers to define disease progression or treatment responses in Stage III and IV treated patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age \> 18 years
2. Primary melanoma \> 1 mm in Breslow depth
3. Stage III or IV disease as determined either by sentinel node biopsy, biopsy of clinically enlarged lymph nodes, and/or imaging. If stage IV, must have tissue biopsy confirming presence of stage IV melanoma
You may not be if
1. Pregnant patients
2. Contraindication to contrasted imaging (due to allergy or renal insufficiency)
